• 1
    Bender A, Sapp M, Schuler G, Steinman RM. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996;196: 1215.
  • 2
    Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20: 62167.DOI: 10.1146/annurev.immunol.20.100301.064828
  • 3
    Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93: 24351.DOI: 10.1002/ijc.1323
  • 4
    Lau R, Wang F, Jeffery G et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24: 6678.DOI: 10.1097/00002371-200101000-00008
  • 5
    Panelli MC, Wunderlich J, Jeffries J et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23: 48798.DOI: 10.1097/00002371-200007000-00013
  • 6
    Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2003;195: 127988.DOI: 10.1084/jem.20012100
  • 7
    Sozzani S, Allavena P, D'Amico G et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 1998;161: 10836.
  • 8
    Della Bella S, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89: 146372.
  • 9
    Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2: 1096103. DOI: 10.1038/nm1096-1096
  • 10
    Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164: 126976.
  • 11
    McIlroy D, Gregoire M. Review: optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 2003;52: 111.
  • 12
    Met Ö, Buus S, Claesson MH. Peptide loaded dendritic cells prime and activate MHC-class I restricted-T cells more efficiently than protein-loaded cross-presenting DC. Cell Immunol 2003;122: 12633.DOI: 10.1016/S0008-8749(03)00128-X
  • 13
    Bennett SR, Carbone FR, Karamelis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997;186: 6570.
  • 14
    Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84: 400827.
  • 15
    Abdi K. Review: IL-12. The role of p40 versus p75. Scand J Immunol 2003;56: 112.DOI: 10.1046/j.1365-3083.2002.01101.x
  • 16
    Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2001;50: 41727.DOI: 10.1007/s002620100215
  • 17
    Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161: 3096102.
  • 18
    Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188: 37386.DOI: 10.1084/jem.188.2.373
  • 19
    Förster R, Schubel A, Breitfeld D et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99: 2333.
  • 20
    Gunn MD, Kyuwa S, Tam C et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189: 45160.DOI: 10.1084/jem.189.3.451
  • 21
    Wei WZ, Ratner S, Shibuya T, Yoo G, Jani A. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. J Immunol Methods 2001;258: 14150.DOI: 10.1016/S0022-1759(01)00484-7
  • 22
    Svane IM, Pedersen AE, Johnsen HE et al. Wildtype and modified p53-peptide pulsed dendritic cells elicit immune and clinical response in patients with advanced breast cancer. Cancer Immunol Immunother 2004;53: 63371.DOI: 10.1007/s00262-003-0493-5
  • 23
    Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27: 31357.
  • 24
    Allsopp CE, Nicholls SJ, Langhorne J. A flowcytometric method to assess antigen-specific proliferative responses of different subpopulations of fresh and cryopreserved human peripheral blood mononuclear cells. J Immunol Methods 1998;214: 17586. DOI: 10.1016/S0022-1759(98)00056-8
  • 25
    Svane IM, Nikolajsen K, Hansen SW, Kamby C, Nielsen D, Johnsen HE. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Bone Marrow Transplant 2002;29: 65966.DOI: 10.1038/sj.bmt.1703521
  • 26
    Josephson K, McPherson DT, Walter MR. Purification, crystallization and preliminary X-ray diffraction of a complex between IL-10 and soluble IL-10R1. Acta Cryst 2001;57: 190811.
  • 27
    Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high-affinity DR-blocking peptides. Immunity 1994;1: 75161.
  • 28
    Grassi F, Dezutter-Dambuyant C, McIlroy D et al. Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. J Leukoc Biol 1998;64: 48493.
  • 29
    Taga K, Tosato G. Review: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992;148: 11438.
  • 30
    Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. Review: The dual role of IL-10. Trends Immunol 2003;24: 3643.DOI: 10.1016/S1471-4906(02)00009-1
  • 31
    Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996;88: 53641.
  • 32
    Zheng LM, Ojcius DM, Garaud F. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184: 57984.DOI: 10.1084/jem.184.2.579
  • 33
    Corinti S, Albanesi C, La Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166: 43128.
  • 34
    Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100: 135461.
  • 35
    Caux C, Vanbervliet B, Massacrier C et al. Regulation of dendritic cell recruitment by chemokines. Transplantation 2002: 73 (Suppl.):711.
  • 36
    Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 1998;95: 25865.DOI: 10.1073/pnas.95.1.258
  • 37
    Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro-and in vivo-derived dendritic cells. J Immunol 1999;162: 385965.
  • 38
    Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171: 627583.
  • 39
    Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998;46: 17584.DOI: 10.1007/s002620050476
  • 40
    Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002;12: 4350.DOI: 10.1006/scbi.2001.0402
  • 41
    Dworacki G, Meidenbauer N, Kuss I et al. Decreased theta expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7 (Suppl.):94755.
  • 42
    Uzzo RG, Rayman P, Kolenko V et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5: 121924.
  • 43
    Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8+CD28– T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003;52: 599607. DOI: 10.1007/s00262-003-0395-6
  • 44
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5: 296370.
  • 45
    Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoetic progenitors. J Immunol 1998;161: 484251.
  • 46
    Satthaporn S, Robins A, Vassanasiri W. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004;53: 510–18.DOI: 10.1007/s00262-003-0485-5
  • 47
    Gabrilovich DI, Corak J, Ciernik IF, Kavanough D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3: 48390.